article thumbnail

The Gains and Pains of Using AI in the Pharmaceutical Industry

HIT Consultant

Contributing factors to this included larger trial sizes, the need to assess health technology, the requirement to provide data on comparative drugs’ effectiveness, and most importantly the high failure rate. A study in 2020 concluded that the estimated median capitalized research and development cost per product was $985 million.

article thumbnail

Verily Powers Otsuka’s Longitudinal Registry to Advance Mental Health Research

HIT Consultant

What You Should Know: – Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka) , a global pharmaceutical company, and Verily Life Sciences LLC (Verily) , a precision health technology company, have teamed up to launch a groundbreaking research initiative called “ My Mental Health Journey.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Philips Appoints Charlotte Hanneman as New CFO, Succeeding Abhijit Bhattacharya

HIT Consultant

Charlotte-Hanneman, CFO at Philips What You Should Know: – Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the appointment of Charlotte Hanneman as its new Chief Financial Officer (CFO). Hanneman brings over 20 years of experience in the MedTech and pharmaceutical industries. – Ms.

article thumbnail

Quantifying the Long-Run Economic and Health Impact of Reduced Intellectual Property Protections for New Drugs

Healthcare ECONOMIST

Some policymakers have called for weakening of intellectual property protections for vaccines and other pharmaceutical products, with the aim to reduce the price and improve access to existing medical technologies, particularly in Eastern Europe and developing countries.

article thumbnail

Book Review: The Right Price

Healthcare ECONOMIST

That the book should be able to so clearly elucidate these issues should not come as a surprise as the authors–Peter Neumann, Joshua Cohen and Daniel Ollendorf–are pre-eminent experts in value-based pricing methodologies for pharmaceuticals. Are high drug prices a good thing? PBMs: The problem or the solution. The spread of HTA.

article thumbnail

myTomorrows Partners with brainstrust to Support Brain Cancer Patients in Accessing Clinical Trials

HIT Consultant

What You Should Know: myTomorrows , a global health technology company connecting patients with all possible treatment options, today announced a new partnership with brainstrust, a UK-based charity that helps people living with a brain tumor reach their potential and thrive.

article thumbnail

Sonde Health Secures $19.25M for Voice-Based Health Monitoring

HIT Consultant

What You Should Know: – Sonde Health , a Boston, MA-based health technology company committed to bringing accessible health monitoring to everyone raises $19.25 Sonde licenses its platform to customers globally in two ways: Health Checks.